to Heal the Mind
Dr. Stan W. Mandel has been successful in starting the entrepreneurship program at Wake Forest University, creating a concentration in entrepreneurship, developing the Elevator Competition, Retail Innovation Challenge, Breast Cancer Startup Competition, and VentuRealization, and launching the Babcock Demon Incubator. Dr. Mandel's other honors include: top national ranking by Princeton Review; winner of the Model MBA Program in Entrepreneurship; and a NASDAQ Entrepreneurial Center of Excellence Award. Personal honors include: recognition for contributions to NCEC, #3 program director by peers, winner of the Irwin McGraw-Hill award for "Innovation in Entrepreneurial Pedagogy," and selected as a USASBE Fellow. Dr. Mandel currently teaches entrepreneurial courses at WFU (UG, MBA, Working Professionals) and mentors startups in a number of domains. Stan’s personal entrepreneurial experience includes startups of three family businesses, a financial institution, a mobile diagnostic health care provider, and several non-profit organizations. He is currently involved as an advisor or director in the startups of new ventures of students, faculty in the medical school, alumni, and area entrepreneurs. During his career, Stan has served on boards and/or as an officer of over 30 organizations within education, health care, finance, retail, manufacturing, e'commerce, and not-for-profits. Mandel is a frequent speaker and has been published/quoted in a variety of business journals (examples include: WSJ, Business Week, and the Harvard Business Review).
Our Chief Executive Officer manages all business operations and provides a vision for the future of EncepHeal Therapeutics, Inc.
Lazarus previously served as project manager for the lead generation program at PatientStar LLC. He graduated from Wake Forest University with his M.A. in Management in 2015 and his B.S. in Biology in 2014.
As Chief Research Officer, Dr. Childers will lead the development of EncepHeal Therapeutics psychostimulant addiction therapeutics. With over 30+ years of experience he is widely regarded as a top expert in the field of biochemical neuropharmacology. Since 1999 his research has had a focus on the identification of potential medications to treat cocaine addiction. As part of that effort, his laboratory has screened over 600 novel compounds at brain target receptors to identify logical candidates for medication development.
As Chief Business Development Officer, Ms. Martin is in charge of identifying potential new assets, pursuing new corporate and institutional partnerships, and detecting new areas of growth.
Martin is a Ph.D. graduate in Molecular Medicine and Translational Science from the Wake Forest School of Medicine. Her thesis was focused on understanding the molecular mechanisms of reprogramming CD4+ T cells using a Sirtuin 1 protein specific inhibitor during acute systemic inflammation from sepsis.
Dr. Peter Sheldrake is an Adjunct Professor of Innovation and Global Business at Wake Forest University. Until recently he was an Adjunct Professor at RMIT University in Melbourne, Australia, where he served as Professor of Business Entrepreneurship for fourteen years. In that role, he was responsible for teaching and conducting research in innovation and entrepreneurship, global business, business strategy, and leadership. In addition to having developed and instructed several executive education classes and university postgraduate courses, Dr. Sheldrake has been a consultant for companies, small businesses, and not-for-profits across the U.S., Australia, and Southeast Asia. He earned his B.A., M.A., and M.Sc. from the University of Cambridge and his Ph.D. from RMIT University.
As Chief Science Officer, Mr. Rahimi oversees the scientific development of each asset and is in charge of identifying new discoveries and technologies for incorporation into our business.
Rahimi earned his B.S. in Biochemistry from the University of St. Thomas, and an M.Sc. in Pharmacology from the University of Minnesota. He is currently a Ph.D. candidate in Integrative Physiology and Pharmacology at Wake Forest School of Medicine. His thesis research concentration is on a potential therapy for the mitigation of chemotherapeutic cardiotoxicity.
Mr. Robert Anderson is an executive with a proven track record of accomplishments in the financial, high-tech, and medical industries. He is a skilled and resourceful manager with broad experience working with senior executives and cross-functional teams. Mr. Anderson previously worked with PointDx, Inc. and served as CEO of GreatWall Systems, Inc. where he raised more than $850K in government grants and $1.2M from private investors. He provides experience in assessing potential strategic initiatives, investment opportunities, mergers and acquisitions, distribution agreements, vendor financial reviews, and joint ventures. Mr. Anderson currently serves as CEO of Causa Research, Inc. where he manages all aspects of the company (including raising capital, managing day-to-day activities, and managing sales and partnerships). Mr. Anderson earned his B.S. in Mathematics with an emphasis in Computer Science from Berea College and his M.B.A. from Wake Forest University.